Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?

Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is defined as a sudden acceleration of the disease with the appearance of pulmonary infiltrates superimposed on the characteristic pattern of IPF that leads to a significant decline in lung function. It has high in-hospital mortality rat...

Descripción completa

Detalles Bibliográficos
Autores: Cuerpo Cardeñosa, Sandra, Moisés, Jorge, Hernández González, Fernanda, Benegas, Mariana, Ramírez Ruz, J. (José), Sánchez, Marcelo, Agustí García-Navarro, Àlvar, Sellarés Torres, Jacobo
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/141668
Acceso en línea:https://hdl.handle.net/2445/141668
Access Level:acceso abierto
Palabra clave:Fibrosi pulmonar
Corticosteroides
Pulmonary fibrosis
Adrenocortical hormones
id ES_cdc409d5c675e93e5edbd92ade09c12f
oai_identifier_str oai:diposit.ub.edu:2445/141668
network_acronym_str ES
network_name_str España
repository_id_str
spelling Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?Cuerpo Cardeñosa, SandraMoisés, JorgeHernández González, FernandaBenegas, MarianaRamírez Ruz, J. (José)Sánchez, MarceloAgustí García-Navarro, ÀlvarSellarés Torres, JacoboFibrosi pulmonarCorticosteroidesPulmonary fibrosisAdrenocortical hormonesAcute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is defined as a sudden acceleration of the disease with the appearance of pulmonary infiltrates superimposed on the characteristic pattern of IPF that leads to a significant decline in lung function. It has high in-hospital mortality rates, despite medical treatment with systematic steroids. We sought to investigate whether there were in-hospital mortality differences according to clinical stratification (AE, suspected AE, or AE of known cause) and/or treatment with systemic steroids. We reviewed the clinical characteristics and outcomes of patients with IPF admitted to our hospital during the years 2003-2014 due to a worsening of their clinical status. We identified 50 IPF patients, 9 with AE (18%), 12 with suspected exacerbation (24%), and 29 with AE of known cause (58%), mostly respiratory infections. In-hospital mortality was similar in the three groups (33% vs. 17% vs. 34%, respectively). Likewise, we did not find differences between them with respect to the use of systemic steroids (length of treatment duration or total dose). Nevertheless, there was an independent association between in-hospital mortality and high average daily steroid dose. We did not observe significant differences in prognosis or use of systemic steroids according to current diagnostic stratification groups in patients hospitalized because of an exacerbation of IPF.2019info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/2445/141668Articles publicats en revistes (Fonaments Clínics)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaIngléshttps://doi.org/10.1177/1479973119869334Chronic Respiratory Disease, 2019, vol. 16, p. 1-8https://doi.org/10.1177/1479973119869334, 2019info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1416682026-05-27T06:46:51Z
dc.title.none.fl_str_mv Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
title Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
spellingShingle Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
Cuerpo Cardeñosa, Sandra
Fibrosi pulmonar
Corticosteroides
Pulmonary fibrosis
Adrenocortical hormones
title_short Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
title_full Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
title_fullStr Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
title_full_unstemmed Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
title_sort Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?
dc.creator.none.fl_str_mv Cuerpo Cardeñosa, Sandra
Moisés, Jorge
Hernández González, Fernanda
Benegas, Mariana
Ramírez Ruz, J. (José)
Sánchez, Marcelo
Agustí García-Navarro, Àlvar
Sellarés Torres, Jacobo
author Cuerpo Cardeñosa, Sandra
author_facet Cuerpo Cardeñosa, Sandra
Moisés, Jorge
Hernández González, Fernanda
Benegas, Mariana
Ramírez Ruz, J. (José)
Sánchez, Marcelo
Agustí García-Navarro, Àlvar
Sellarés Torres, Jacobo
author_role author
author2 Moisés, Jorge
Hernández González, Fernanda
Benegas, Mariana
Ramírez Ruz, J. (José)
Sánchez, Marcelo
Agustí García-Navarro, Àlvar
Sellarés Torres, Jacobo
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Fibrosi pulmonar
Corticosteroides
Pulmonary fibrosis
Adrenocortical hormones
topic Fibrosi pulmonar
Corticosteroides
Pulmonary fibrosis
Adrenocortical hormones
description Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is defined as a sudden acceleration of the disease with the appearance of pulmonary infiltrates superimposed on the characteristic pattern of IPF that leads to a significant decline in lung function. It has high in-hospital mortality rates, despite medical treatment with systematic steroids. We sought to investigate whether there were in-hospital mortality differences according to clinical stratification (AE, suspected AE, or AE of known cause) and/or treatment with systemic steroids. We reviewed the clinical characteristics and outcomes of patients with IPF admitted to our hospital during the years 2003-2014 due to a worsening of their clinical status. We identified 50 IPF patients, 9 with AE (18%), 12 with suspected exacerbation (24%), and 29 with AE of known cause (58%), mostly respiratory infections. In-hospital mortality was similar in the three groups (33% vs. 17% vs. 34%, respectively). Likewise, we did not find differences between them with respect to the use of systemic steroids (length of treatment duration or total dose). Nevertheless, there was an independent association between in-hospital mortality and high average daily steroid dose. We did not observe significant differences in prognosis or use of systemic steroids according to current diagnostic stratification groups in patients hospitalized because of an exacerbation of IPF.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/141668
url https://hdl.handle.net/2445/141668
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1177/1479973119869334
Chronic Respiratory Disease, 2019, vol. 16, p. 1-8
https://doi.org/10.1177/1479973119869334
dc.rights.none.fl_str_mv , 2019
info:eu-repo/semantics/openAccess
rights_invalid_str_mv , 2019
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Articles publicats en revistes (Fonaments Clínics)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419884276875264
score 15,301603

Similares en LA Referencia